NCT05883956 2025-03-20PREFER-HMAOtsuka Australia Pharmaceutical Pty LtdPhase 3 Active not recruiting13 enrolled
NCT02907359 2024-08-27Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsAstex Pharmaceuticals, Inc.Phase 3 Completed417 enrolled 24 charts
NCT03306264 2024-08-27Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLAstex Pharmaceuticals, Inc.Phase 3 Completed227 enrolled 37 charts 2 FDA
NCT00043381 2024-08-02Decitabine Versus Supportive Care in Adults With Advanced-stage MDSAstex Pharmaceuticals, Inc.Phase 3 Completed160 enrolled
NCT04842604 2023-12-18Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLPfizerPhase 3 Completed14 enrolled 11 charts
NCT01928537 2020-06-30Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineTraws Pharma, Inc.Phase 3 Completed67 enrolled
NCT00109538 2015-05-01Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)Merck Sharp & Dohme LLCPhase 3 Terminated47 enrolled
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts